Christopher R. Moyes

Statistics

Publications

Citations

889

H-Index

Active since

1993

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

MSD (UK) Limited (United Kingdom)

United States Military Academy

Christopher R. Moyes is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicinal chemistry, and medicine.

Publications per year

1993–2022

Publications

Fluorination of 3-(3-(Piperidin-1-yl)propyl)indoles and 3-(3-(Piperazin-1-yl)propyl)indoles Gives Selective Human 5-HT1D Receptor Ligands with Improved Pharmacokinetic Profiles

Monique B. van Niel, Ian Collins, Margaret S. Beer et al. · Journal of Medicinal Chemistry · 1999 · 157 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Anxiogenic properties of an inverse agonist selective for α3 subunit‐containing GABAA receptors

John Atack, Peter H. Hutson, Neil Collinson et al. · British Journal of Pharmacology · 2005 · 134 citations · Full text

Medicine, Neuroscience, Pharmacology +17

3-Heteroaryl-2-pyridones: Benzodiazepine Site Ligands with Functional Selectivity for α2/α3-Subtypes of Human GABAA Receptor-Ion Channels

Ian Collins, Christopher R. Moyes, William B. Davey et al. · Journal of Medicinal Chemistry · 2002 · 109 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as High Affinity, Selective, and Orally Bioavailable h5-HT2A Receptor Antagonists

Michael Rowley, David J. Hallett, Simon Goodacre et al. · Journal of Medicinal Chemistry · 2001 · 109 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Discovery of Vibegron: A Potent and Selective β3Adrenergic Receptor Agonist for the Treatment of Overactive Bladder

Scott D. Edmondson, Cheng Zhu, Nam Fung Kar et al. · Journal of Medicinal Chemistry · 2015 · 102 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

1–5 of 12